Last reviewed · How we verify
FS-1
At a glance
| Generic name | FS-1 |
|---|---|
| Sponsor | Scientific Center for Anti-infectious Drugs, Kazakhstan |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- "Efesovir" (FS-1) for COVID-19, Phase 2 (PHASE2)
- Schroth Exercise Versus Functional Electrical Stimulation in Adolescent With Spinal Deformities (NA)
- FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis (PHASE3)
- The Effects of Accelerometer Triggered Functional Electrical Stimulation on Post-Stroke Hemiplegic Shoulder Subluxation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FS-1 CI brief — competitive landscape report
- FS-1 updates RSS · CI watch RSS
- Scientific Center for Anti-infectious Drugs, Kazakhstan portfolio CI